Fangzhou Inc. Filed for Listing on the Hong Kong Stock Exchange

The Hong Kong Stock Exchange recently disclosed that Fangzhou Inc. has filed an application for listing on the Main Board of the HKSE, with Citi, UBS, and ABC International as joint sponsors. Fangzhou Inc. is the largest online chronic disease management platform in China in terms of average monthly active users in 2021. This company also provides online retail pharmacy services, offering a wide range of pharmaceutical and healthcare products directly to its customers.

As of June 30, 2022, Fangzhou Inc. had approximately 30.9 million registered users. In terms of financial data, Fangzhou Inc.’s revenue for the six months of 2022 ended on June 30 was RMB 993 million yuan (USD $141.7 million), of which the company’s gross profit was RMB 152 million yuan (USD $21.5 million), with a gross profit margin of 15.3%.(Source: finance.sina)

Visit HPA-China’s Information Hub, CLICK HERE